India’s Glenmark Seeks Arbitration Of Contract Dispute With Napo Of U.S.
This article was originally published in PharmAsia News
Executive Summary
India’s Glenmark formally challenged the decision by U.S.-based Napo Pharmaceuticals to cancel their contract involving development and marketing of the diarrhea drug crofelemer.